HOOKIPA Pharma To Report Third Quarter 2019 Financial Results on November 12, 2019
November 04 2019 - 8:00AM
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing
a new class of immunotherapeutics targeting infectious diseases and
cancers based on its proprietary arenavirus platform, will announce
financial results for the third quarter ended September 30, 2019 on
Tuesday, November 12, 2019, after the NASDAQ market close.
The Company will not be conducting a conference call in
conjunction with this earnings release. Until otherwise noted, the
Company will only conduct an earnings conference call in
conjunction with its fourth quarter earnings releases.
About
HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical
stage biopharmaceutical company developing a new class of
immunotherapeutics, targeting infectious diseases and cancers based
on its proprietary arenavirus platform that is designed to
reprogram the body’s immune system.
HOOKIPA’s proprietary arenavirus-based
technologies, VaxWave®*, a replication-deficient viral vector, and
TheraT®*, a replication-attenuated viral vector, are designed to
induce robust antigen specific CD8+ T cells and
pathogen-neutralizing antibodies. Both technologies are designed to
allow for repeat administration while maintaining an immune
response. TheraT® has the potential to induce CD8+ T cell response
levels previously not achieved by other published immuno-therapy
approaches. HOOKIPA’s “off-the-shelf” viral vectors target
dendritic cells in vivo to activate the immune system.
HOOKIPA’s VaxWave®-based prophylactic
cytomegalovirus vaccine candidate is currently in a Phase 2
clinical trial in patients awaiting kidney transplantation from
living cytomegalovirus-positive donors. To expand its infectious
disease portfolio, HOOKIPA has entered into a collaboration and
licensing agreement with Gilead Sciences, Inc. to jointly research
and develop functional cures for HIV and Hepatitis B infections.
HOOKIPA is building a proprietary immuno-oncology pipeline by
targeting virally mediated cancer antigens, self-antigens and
next-generation antigens.
TheraT® and VaxWave® are not approved anywhere
globally and their safety and efficacy have not been
established.
Find out more about HOOKIPA online at
www.hookipapharma.com.
*Registered in Europe; Pending in the US.
For further information, please contact:
Media |
Investors |
Nina Waibel |
Matt Beck |
Senior Director - Communications |
Executive Director - Investor Relations |
Nina.Waibel@HookipaPharma.com |
Matthew.Beck@HookipaPharma.com |
|
|
Media enquiries |
|
Sue Charles/ Ashley Tapp |
|
Instinctif Partners |
|
Hookipa@Instinctif.com |
|
+44 (0)20 7457 2020 |
|
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Aug 2024 to Sep 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Sep 2023 to Sep 2024